期刊
CLINICAL INFECTIOUS DISEASES
卷 53, 期 2, 页码 158-163出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir340
关键词
-
资金
- Sharp Healthcare Foundation
- Cubist Pharmaceuticals
- Astellas Pharmaceuticals
- Cubist
- Pfizer Pharmaceuticals
- Astellas
- Ortho-McNeil Pharmaceuticals
We used daptomycin plus antistaphylococcal beta-lactams (ASBL) to clear refractory MRSA bacteremia. In vitro studies showed enhanced daptomycin bactericidal activity, increased membrane daptomycin binding, and decrease in positive surface charge induced by ASBLs against daptomycin nonsusceptible MRSA. Addition of ASBLs to daptomycin may be of benefit in refractory MRSA bacteremia. (Although the official designation is daptomycin nonsusceptiblity, we will use the term daptomycin-resistance in this paper for facility of presentation.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据